Pre-launch · We're opening Reserve Meds to a limited first cohort. Join the waitlist ›
Home / Drugs / Hernexeos

Hernexeos, daridorexant class

Named-patient access overview. Hernexeos is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.

About Hernexeos

Hernexeos (daridorexant class) is manufactured by Idorsia (verify) and indicated for Insomnia, OUT OF SCOPE (daridorexant class = DEA Schedule IV dual orexin receptor antagonist; PlatformCo does not handle controlled substances. Fatima's DEA-registered entity may pursue separately. Note: drug-name mapping 'Hernexeos' is uncertain, verify FDA label before any future action.). It is a HER2 TKI approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.

How Reserve Meds coordinates Hernexeos

  1. Patient or treating physician submits a named-patient request.
  2. Clinical team verifies appropriateness of Hernexeos for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific NPP / personal-import documentation is prepared.
  5. Hernexeos is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).

Access by country

Reserve Meds publishes a detailed country deep-dive for Hernexeos in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.

Hernexeos in BahrainFull deep-dive on regulatory pathway, costs, timing Hernexeos in BangladeshFull deep-dive on regulatory pathway, costs, timing Hernexeos in EgyptFull deep-dive on regulatory pathway, costs, timing Hernexeos in IndiaFull deep-dive on regulatory pathway, costs, timing Hernexeos in JordanFull deep-dive on regulatory pathway, costs, timing Hernexeos in KuwaitFull deep-dive on regulatory pathway, costs, timing Hernexeos in Saudi ArabiaFull deep-dive on regulatory pathway, costs, timing Hernexeos in Sri LankaFull deep-dive on regulatory pathway, costs, timing Hernexeos in TurkeyFull deep-dive on regulatory pathway, costs, timing

Start a request for Hernexeos

Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.

Join the Hernexeos waitlist

About Hernexeos

Neurology
Manufacturer: Idorsia (verify)
Modality: HER2 TKI
Generic: daridorexant class

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides